Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Summary
3. Progression of IVIg use worldwide (1)
4. Progression of IVIg use worldwide (2)
5. Worldwide IVIg use
6. Causes of this evolution
7. IVIg composition (1)
8. IVIg composition (2)
9. IVIg mechanisms of action
10. IVIg mechanisms of action (1,2)
11. Established indications for IVIg
12. Established indications for IVIg: summary
13. Humoral immunodeficiency syndromes
14. Immune thrombocytopenic purpura (ITP) (1)
15. Immune thrombocytopenic purpura (ITP) (2)
16. Pure red cell aplasia (PRCA)
17. Allogeneic bone marrow transplantation (ABMT)
18. Kawasaki disease
19. Guillain-barr syndrome (GBS)
20. Chronic inflammatory demyelinating polyneuropathy
21. CIDP: focus on a randomized trial
22. Acute myasthenia
23. Refractory inflammatory dermatomyositis
24. Refractory inflammatory polymyositis
25. Multifocal motor neuropathy
26. IVIg in birdshot retinochoroidopathy
27. Stiff-man syndrome
28. IVIg - Indications to be further assessed
29. IVIg - Indications to be further assessed: summary
30. Multiple sclerosis (MS)
31. Relapsing ANCA-positive vasculitis
32. Hemophagocytic syndrome of infectious origin
33. Streptococcal/Staphylococcal shock syndrome
34. Lyell syndrome: toxic epidermal necrolysis
35. Ocular cicatricial pemphigoid (OCP)
36. Analysis of the steroid sparing effect of IVIg
37. Steroid sparing effect of IVIg (1)
38. Steroid sparing effect of IVIg (2)
39. Conclusion and perspectives
40. Conclusion: perspectives

Topics Covered

• The use of intravenous immunoglobulins (IVIg) as therapeutic proteins
• Use of IVIg to provide effective treatment for autoimmune thrombocytopenic purpura
• Use of IVIg in a large range of autoimmune or systemic inflammatory diseases
• Increase in worldwide IVIg demand
• Increased evidence showing the efficacy of IVIg
• Mechanisms for the action of IVIg in autoimmune diseases
• Need for classification of the recommendations for use
• Clinical indications for IVIg therapy

Links

Series:

• Autoimmunity

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. Zera Tellier has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.